Fière D, Marty M, Solal-Celigny P, Harousseau J L, Gorin N C, Desablens B, Brière J, David B, Bordessoule D, Hayat M
Service d'Hématologie, Hôpital Edouard Herriot, Lyon.
Presse Med. 1989 Feb 11;18(5):221-3.
Between April and December, 1982, a multicentre pilot study was conducted in 45 patients aged from 16 to 73 years suffering from acute lymphoblastic leukaemia to test the feasibility of an intensive and short induction phase followed by an early consolidation phase. All patients received a 5-day course of induction chemotherapy with prednisone, vincristine, AraC and rubidazone, then a "triple A regimen" for consolidation, consisting of adriamycin, AraC and asparaginase. The complete remission rate was 73 per cent. Toxicity during induction was characterized by frequent infections, but the consolidation treatment was well tolerated. Thus, the sequence intensive induction-early consolidation proved feasible and acceptable. In terms of survival, 8 out of the 33 patients in remission are still alive and well after more than 4 1/2 years.
1982年4月至12月期间,对45例年龄在16岁至73岁之间的急性淋巴细胞白血病患者进行了一项多中心试点研究,以测试强化短诱导期随后早期巩固期的可行性。所有患者接受了为期5天的诱导化疗,使用泼尼松、长春新碱、阿糖胞苷和柔红霉素,然后接受“三联A方案”进行巩固,该方案由阿霉素、阿糖胞苷和天冬酰胺酶组成。完全缓解率为73%。诱导期间的毒性表现为频繁感染,但巩固治疗耐受性良好。因此,强化诱导-早期巩固的方案被证明是可行且可接受的。就生存情况而言,33例缓解患者中有8例在超过4年半后仍然健在。